Benzgalantamine gluconate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for benzgalantamine gluconate and what is the scope of freedom to operate?
Benzgalantamine gluconate
is the generic ingredient in one branded drug marketed by Alpha Cognition and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for benzgalantamine gluconate
| International Patents: | 27 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for benzgalantamine gluconate |
| DailyMed Link: | benzgalantamine gluconate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for benzgalantamine gluconate
Generic Entry Date for benzgalantamine gluconate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for benzgalantamine gluconate
US Patents and Regulatory Information for benzgalantamine gluconate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-003 | Jul 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-003 | Jul 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for benzgalantamine gluconate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2022208641 | ⤷ Start Trial | |
| Canada | 3205859 | ⤷ Start Trial | |
| China | 116761612 | ⤷ Start Trial | |
| European Patent Office | 4029867 | ⤷ Start Trial | |
| European Patent Office | 4277907 | ⤷ Start Trial | |
| Israel | 303907 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
